Debiopharm’s portfolio investment company Immunexpress has received a grant from BARDA (Biomedical Advanced Research and Development Authority), a division of the U.S. Department of Health and Human Services for up to just under $600K. Immunexpress will use this funding will to continue the the development required to validate the role of SeptiCyte® RAPID as a triage tool to help identify COVID-19 patients with an elevated risk for sepsis, and pursue U.S. Food and Drug Administration Emergency Use Authorization (EUA).
Preliminary research has revealed sepsis as the most frequently observed complication associated with COVID-19 mortality. Early diagnosis of bacterial or viral sepsis with SeptiCyte® RAPID can promote rapid initiation of appropriate sepsis management, potentially to saving lives and increasing efficiency of the use of limited resources.
Access their full press release here.